According to the Chongqing Development and Reform Commission and the Municipal Bureau of Commerce, the city will continue its policies to promote automobile consumption in 2023. They have formulated and implemented a new energy vehicle subsidy policy and implemented subsidy promotions to benefit consumers. The municipal government will provide subsidies of 1,000 to 3,000 yuan per vehicle to consumers purchasing new passenger cars (including new energy and fuel vehicles), with a cumulative subsidy of 30 million yuan benefiting 11,000 consumers and driving sales of 1.913 billion yuan. This has effectively stimulated the potential of automobile consumption. In the first half of the year, the city's retail sales of automobile products increased by 6.2%, a 12.4 percentage point rebound compared to the first quarter. This contributed to a 1.8 percentage point increase in the overall retail sales of restricted commodities in the city. Among them, the retail sales of new energy vehicles gr
The 2023 Shenzhen International Biomedical Industry Innovation and Development Conference will be held in Shenzhen Pingshan.
The conference will take place from July 27th to 29th at the Yanzi Lake International Exhibition Center in Shenzhen Pingshan. Themed "Cross-border Integration, Deep Into the Future," the conference will include one closed-door session for medical industry leaders, one keynote forum, and nine specialized thematic forums. The focus will be on innovative medical devices, emerging biopharmaceuticals, industry trends, and business services such as international expansion and investment financing. This conference aims to create a high-standard, high-quality, and internationally recognized event in the field of international biomedical industry.
The conference is jointly organized by the Shenzhen Municipal People's Government, the Pingshan District People's Government of Shenzhen, the Dapeng New District Management Committee of Shenzhen, the Development and Reform Commission of Shenzhen, and the Science and Technology Innovation Commission of Shenzhen.
Attendees at the press conference included Deng Yandong, Standing Committee Member and Minister of the Publicity Department of the Pingshan District Committee; Wang Jun, Deputy Director of the Development and Reform Commission of Shenzhen; Zhong Hai, Deputy Director of the Science and Technology Innovation Commission of Shenzhen; Wu Bo, Member of the Party Working Committee and Deputy Director of the Management Committee of Dapeng New District; and Cheng Zengjiang, the initiator of the Teyuxiyi Forum, who introduced the relevant information and answered questions from the press.
It is worth noting that the Shenzhen International Biomedical Industry Innovation and Development Conference has been successfully held in Pingshan District for five consecutive times. Starting this year, the "Shenzhen International Biomedical Industry Innovation and Development Conference" and the "Shenzhen International Biomedical Industry Summit Forum," both held in Pingshan District, will be held in the summer and winter respectively. This will establish a pattern of "relevance in both seasons," ensuring that the development of the Shenzhen biotechnology industry remains vibrant throughout the year.
This conference promises to be full of highlights.
First, it will showcase the results of the "cross-border, breaking barriers, and integration" achievements in the development of the Shenzhen biotechnology industry. The conference will feature thematic forums on IVD and innovative medical devices, IT&BT integration, and future healthcare, fully demonstrating the theme of "cross-border integration" and illuminating the path for high-quality development of the Shenzhen biotechnology industry.
Second, the conference will provide rich content and focus on global hot topics. The conference will include one closed-door session for medical industry leaders, one keynote forum, and nine specialized thematic forums. The main forum will feature conference reports and roundtable discussions on national medical and health policies, high-end medical devices, the latest achievements in medical health, domestic and international industry-academia-research collaboration, and medical and health investment. The sub-forums will focus on areas such as chemical pharmaceuticals, new biopharmaceuticals, international expansion, frontier technology transformation, and pharmaceutical cooperation and investment. With the goal of promoting the development of the Shenzhen (Pingshan) pharmaceutical industry, the forums will look globally, analyze industry trends, and lead innovative investment.
Lastly, esteemed experts from various fields will come together to discuss the forefront of the industry. The conference has invited 13 renowned academicians from China, the United States, Russia, Canada, Europe, and other countries, as well as the CEOs of five major IT giants, over 20 former FDA experts, and directors and professors from academic and medical institutions such as Shenzhen Third People's Hospital, Johns Hopkins University, Peking University School of Pharmacy, Southern University of Science and Technology Biomedical Research Institute, and Shenzhen Technology University School of Pharmacy. These experts will analyze industry trends, explore technological frontiers, and provide insights into innovative investment, making valuable contributions to the development of the Shenzhen biotechnology industry.
Four, Unprecedented Scale, Achieving Cross-Regional Collaboration
This conference, spanning 2 days, is expected to host over 1000 participants in person, with an additional estimated 50,000 participants online. Moreover, this conference will achieve cross-regional collaboration by setting up a sub-forum in the Dapeng New District, contributing powerful support to the construction of Shenzhen as a demonstration zone for life and health innovation in the Guangdong-Hong Kong-Macao Greater Bay Area, and the creation of an internationally renowned hub for the biopharmaceutical industry.
Biopharmaceuticals are widely recognized as a "sunrise industry." In recent years, Shenzhen has vigorously developed its biopharmaceutical industry, making significant progress in various aspects, such as the scale of the industry, innovation capabilities, drug research and development, specialized parks, industry financing, talent aggregation, and regional layout. This progress has been achieved through measures such as the improvement of specialized industrial policies, the promotion of major innovation platforms, and the continuous optimization of the industrial ecosystem.
Data released during the press conference showed that in 2022, the operating income of pharmaceutical enterprises in Shenzhen reached 48.7 billion yuan, with 6 Shenzhen enterprises making it onto the "2022 Top 100 Chinese Pharmaceutical Companies" list.
Furthermore, with a focus on the well-being of the people and a dedication to high-level scientific self-reliance, Shenzhen continues to improve its scientific and technological innovation system to support the high-quality development of the biopharmaceutical industry. The city is accelerating the construction of major innovation platforms such as the Shenzhen Institute of Advanced Technology and the Shenzhen Bay Laboratory. It has also established over 500 innovation carriers at various levels in the field of biopharmaceuticals. In addition, the city has established 1 national-level clinical medicine research center, 4 provincial-level centers, and 14 municipal-level centers, fully supporting the strategic development of the Greater Bay Area as an international scientific and technological innovation center.
The press conference also highlighted the progress made in the construction of the Ping Shan-Dapeng Guangdong-Hong Kong-Macao Greater Bay Area Health Innovation Demonstration Zone. This demonstration zone, planned jointly by the Ministry of Science and Technology and the Shenzhen Municipal Government, is a new type of innovation platform that relies mainly on the Shenzhen National Biotechnology Base and the Baishilong Core Startup Zone of the Shenzhen International Biotech Valley. Its focus is on the development of three strategic emerging industries: biopharmaceuticals, medical devices, and the health industry, as well as two future industries: cell and gene technology, and brain science and artificial intelligence. The innovation of the demonstration zone follows a model of "coordination between the city and the district, collaboration among departments" and is being built through joint efforts between the municipal government and the district government. This creates a development pattern that complements other key areas such as Qianhai, Hetao, and Guangming, and fosters a strong and coordinated development layout. The ultimate goal is to create a dynamic source of high-quality development for Shenzhen's biopharmaceutical industry.
As the main park and core area for the development and aggregation of the bio-industry in Shenzhen, Ping Shan District is home to the country's first and only national bio-industry base. It is also the core park of Shenzhen National High-Tech Zone, known as the "most important platform and industrial space for Shenzhen's biopharmaceutical industry." In recent years, it has made remarkable achievements in building an ecological system that encompasses the entire chain of "research and development + transformation + production."
Currently, the bio-industry in Ping Shan has formed an advanced manufacturing cluster with a focus on biopharmaceuticals, high-end medical devices, and the health industry. With an average annual increase of over 120 enterprises, the total number of enterprises has exceeded 1,000. The annual growth rate of output value is over 20%. Leading industry players such as Sanofi Pasteur and China National Pharmaceutical Group have been attracted to the area, as well as innovative companies like Prukkin and Huaxian Pharmaceutical. This has established the "Shenzhen BioPark" as a new landmark in the industry, marking its entrance into a period of rapid growth and prosperity.
Comments
Post a Comment